Carbidopa levodopa half lifeHow supplied stalevo® carbidopa, levodopa and entacapone ; is supplied as film-coated tablets for oral administration in the following three strengths: stalevo 50 film-coated tablets containing 1 5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone.
Pleger and Ragert Jacobs BL, Fornal CA. Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology. 1999; 21: 9S-15S. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotoninspecific, second-generation antidepressant. Pharmacotherapy. 1987; 7: 1-15 Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 1993; 5: 322-9. Pleger B, Schwenkreis P, Grunberg C, Malin JP, Tegenthoff M. Fluoxetine facilitates use-dependent excitability of human primary motor cortex. Clin Neurophysiol. 2004; 115: 2157-63. Ilic TV, Korchounov A, Ziemann U. Complex modulation of human motor cortex excitability by the specific serotonin re-uptake inhibitor sertraline. Neurosci Lett. 2002; 319: 116-20. Loubinoux I, Boulanouar K, Ranjeva JP, Carel C, Berry I, Rascol O, Celsis P, Chollet F. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab. 1999; 19: 1365-75. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996; 27: 1211-4. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001; 50: 718-29. Loubinoux I, Pariente J, Rascol O, Celsis P, Chollet F. Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. Neuropsychologia. 2002; 40: 1815-21. Loubinoux I, Pariente J, Boulanouar K, Carel C, Manelfe C, Rascol O, Celsis P, Chollet F. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage. 2002; 15: 26-36. Yamazaki J, Fukuda H, Nagao T, Ono H. 5-HT2 5-HT1C receptormediated facilitatory action on unit activity of ventral horn cells in rat spinal cord slices. Eur J Pharmacol. 1992; 220: 237-42. Hrdina PD, Vu TB. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse. 1993; 14: 324-31. Chen Y, Peng L, Zhang X, Stolzenburg JU, Hertz L. Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells. Brain Res Bull. 1995; 38: 153-9. Palvimaki EP, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J. Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology Berl ; . 1994; 115: 543-6. Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W. Changes in human motor cortex excitability induced by dopaminergic and antidopaminergic drugs. Electroencephalogr Clin Neurophysiol. 1997; 105: 430-7. Mukand JA, Guilmette TJ, Allen DG, Brown LK, Brown SL, Tober KL, Vandyck WR. Dopaminergic therapy with carbidopa Ldopa for left neglect after stroke: a case series. Arch Phys Med Rehabil. 2001; 82: 1279-82. Scheidtmann K, Fries W, Mller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001; 358: 787-90. Scheidtmann K. Advances in adjuvant pharmacotherapy for motor rehabilitation: effects of levodopa. Restor Neurol Neurosci. 2004; 22: 393-8. Garraghty PE, Muja N. NMDA receptors and plasticity in adult primate somatosensory cortex. J Comp Neurol. 1996; 367: 319-26. Ziemann U, Muellbacher W, Hallett M, Cohen LG. Modulation of practice-dependent plasticity in human motor cortex. Brain. 2001; 124: 1171-81 and clarinex. Group C Healthy Volunteers 21.3 10.9% * 20.2 10.2% 8.1 * 8.7 4.7, for instance, carbidopa levadopa. Pharmacotherapy self-assessment program 6: cardiology module, 2007 and clindamycin. Carbidopa efficacyLODOSYN AMANTADINE AMANTADINE HCL AMANTADINE HCL AMANTADINE HCL SYMMETREL APOKYN CARBIDOPA-LEVODOPA SINEMET-10 100 SINEMET-25 100 SINEMET-25 250 CARBIDOPA LEVODOPA CARBIDOPA-LEVODOPA SINEMET CR PARCOPA STALEVO 100 STALEVO 150 STALEVO 50 COMTAN PERMAX MIRAPEX REQUIP ELDEPRYL SELEGILINE HCL SELEGILINE HCL TASMAR BENZTROPINE MESYLATE AKINETON KEMADRIN TRIHEXYPHENIDYL HCL TRIHEXYPHENIDYL HCL CARBIDOPA AMANTADINE HCL AMANTADINE HCL AMANTADINE HCL AMANTADINE HCL AMANTADINE HCL APOMORPHINE HCL CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA CARBIDOPA LEVODOPA ENTACAPONE CARBIDOPA LEVODOPA ENTACAPONE CARBIDOPA LEVODOPA ENTACAPONE ENTACAPONE PERGOLIDE MESYLATE PRAMIPEXOLE DI-HCL ROPINIROLE HCL SELEGILINE HCL SELEGILINE HCL SELEGILINE HCL TOLCAPONE BENZTROPINE MESYLATE BIPERIDEN HCL PROCYCLIDINE HCL TRIHEXYPHENIDYL HCL TRIHEXYPHENIDYL HCL 3 1 Tablet Capsule Capsule Syrup Tablet Tablet Cartridge Tablet Tablet Tablet Tablet Tablet SA Tablet SA Tablet SA Tablet, Disper. Lingual Tablet Tablet Tablet Tablet Tablet Tablet Tablet Capsule Capsule Tablet Tablet Tablet Tablet Tablet Elixir Tablet and clobetasol. The authors thank Astrid Krolik and Marianne Koch for expert technical assistance. References 1. Frank RN. On the pathogenesis of diabetic retinopathy. Ophthalmology. 1991; 98: 586-593. Sims DE. Recent advances in pericyte biology-implications for health and disease. Can J Cardiol. 1991; 7: 431-443. Helbig H, Kornacker S, Berweck S, et al. Membrane potentials in retinal capillary pericytes: Excitability and effect of vasoactive substances. Invest Ophthalmol VisSci. 1992; 24: 2105-2112. Downing SE, Lee JC, Matisoff DN. Coronary blood flow in the diabetic lamb with metabolic acidosis. AmJ Physiol. 1980; 238: H263-H268. 5. Liang CS, Doherty JU, Faillace R, et al. Insulin infusion in conscious dogs: Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. Clin Invest. 1982; 69: 1321-1336. Iannacone ST, Li KX, Sperelakis N, et al. Insulin-induced hyperpolarization in mammalian skeletal muscle. Am] Physiol. 1989; 256: C368-C374. Carbidopa with 5-htp1848. Thornalley PJ, McLellan AC, Lo TW, Benn J, Sonksen PH: Negative association between erythrocyte reduced glutathione concentration and diabetic complications. Clin Sci Lond ; 91: 575-582, 1996 Thornalley PJ, Edwards LG, Kang Y, Wyatt C, Davies N, Ladan MJ, Double J: Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol 51: 1365-1372, 1996 Thornalley PJ: Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27: 565-573, 1996 Thornalley PJ, Ladan MJ, Ridgway SJ, Kang Y: Antitumor activity of S- pbromobenzyl ; glutathione diesters in vitro: a structure-activity study. J Med Chem 39: 3409-3411, 1996 Thornalley PJ: Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol Noisy -le-grand ; 44: 1013-1023, 1998 Thornalley PJ: Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 111-112: 137-151, 1998 Thornalley PJ, Minhas HS: Rapid hydrolysis and slow alpha, beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem Pharmacol 57: 303-307, 1999 Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344 Pt 1: 109116, 1999 Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O, Dawnay A: Mass spectrometric monitoring of albumin in uremia. Kidney Int 58: 2228-2234, 2000 Thornalley PJ, Yurek-George A, Argirov OK: Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3deoxyglucosone under physiological conditions. Biochem Pharmacol 60: 55-65, 2000 Thornalley PJ, Jahan I, Ng R: Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J Biochem Tokyo ; 129: 543-549, 2001 Thornalley PJ: Isothiocyanates: mechanism of cancer chemopreventive action. Anticancer Drugs 13: 331-338, 2002 Thornalley PJ: Methods for studying the binding of advanced glycated proteins to receptors for advanced glycation endproducts AGE receptors ; . Methods Mol Biol 196: 49-62, 2002 Thornalley PJ: Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 50: 37-57, 2002 Thornalley PJ: The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 31: 13411342, 2003 Thornalley PJ: Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 31: 1372-1377, 2003 Thornalley PJ: Use of aminoguanidine Pimagedine ; to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419: 31-40, 2003 Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A: Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375: 581-592, 2003 Thornalley PJ: Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31: 1343-1348, 2003 Thornalley PJ: Glycation, receptor-mediated cell activation and vascular complications of diabetes. Diab Vasc Dis Res 1: 21-22, 2004 Thornalley PJ: Glycation free adduct accumulation in renal disease: the new AGE. Pediatr Nephrol 20: 1515-1522, 2005 Thornalley PJ: Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 1043: 111-117, 2005 Thornalley PJ: Measurement of protein glycation, glycated peptides, and glycation free adducts. Perit Dial Int 25: 522-533, 2005 Thornalley PJ: Unease on the role of glyoxalase 1 in high-anxiety-related behaviour. Trends Mol Med 12: 195-199, 2006 Thornalley PJ: Advanced glycation end products in renal failure. J Ren Nutr 16: 178-184, 2006 Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, Schafers M, von Wnuck LK, Jankowski J, Jankowski V, Chun J, Zidek W, van der GM and cutivate and carbidopa, for instance, carbifopa and levadopa. Magpie Trial Co-ordinating Centre, lnstitute of Health Sciences. Headington. Oxford OX3 7LF, lJK. Albuminuria and fractional albumin clearance were increased in both groups during the study period. Changes were only significant in the fish oil group after 12 months. Increase in albuminuria after 12 months: Fish oil 22% 95% CI: 146 ; , Olive oil 15% 95% CI: 1149 ; Change in fish oil group was 1.05 CI: 0.781.43 ; times that in the olive oil group non-significant ; Intention to treat analysis including all patients having measurements performed on treatment revealed the same results. Increase in fractional albumin clearance after 12 months: Fish oil 33% CI: 1095% ; , Olive oil 1271% ; non-significant ; There were no changes within or between the groups in 24h excretion or fractional clearance of IgG or IgG4 Urinary excretion of retinal binding protein was significantly increased in both groups after 12 months. Glomerular filtration rate Rate of decline of glomerular filtration rate: Fish oil 10.69.7 ml min year vs. Olive oil 4.59.7 ml min year p 0.1 ; Mean difference between the two groups 6.1 95%CI: 1.413.5 ; ml min year. Rate of decline of creatinine clearance rate: Fish oil 0.88.7ml min year, Olive oil 14.78.0 ml min year non-significant ; Serum creatinine rose significantly in both groups IURP YV PROO DW EDVHOLQH WR YV PROO DIWHU months in the fish oil and olive oil groups, respectively p less than0.05 compared to baseline ; There were no significant changes in 24 h ambulatory blood pressure in either groups during the study. Protein intake was stable in the two groups at an average of 1.070.1 and 1.100.07 g kg day in fish and olive oil groups respectively. Plasma triglycerides and VLDL cholesterol decreased significantly at 6 and 12 months and total cholesterol and LDL cholesterol increased significantly at 6 months in the fish oil group. Mean body weight increased slightly in all patients from 71.22.1 at baseline to 72.32.1 kg at 12 months, probably due to lack of compliance with dietary calorie reduction. In each treatment group univariate linear regression between change in albuminuria and mean values of GFR, ambulatory BP, HbA1c, total cholesterol, triglycerides and increase in platelet eicosapentaenoic acid revealed no significant association. A significant correlation was found between rate of decline in GFR and plasma total cholesterol was identified in both groups: r 0.24, p 0.04 and r 0.31, p 0.02 in the fish oil and control groups respectively. Side effects No significant side effects were observed in patients completing the study. 17% of participants in the fish oil group withdrew due to nausea. This could be avoided in future by use of encapsulated codliver oil. Ib Follow-up: 1 year 4 week run in period where all patients received 21 ml olive oil and cyproheptadine. THAI NAKORN PATANA PROGRESS MED. KENYAKU LTD KENYAKU LTD PHARMASANT LABS UNISON UNISON BOOTS BEMED PROGRESS MED. OSOTH INTER LABORA PROGRESS MED. CHAROEN BHAESAJ H.K PHARMACEUTICAL K.B.PHARMA MANUF OSOTH INTER LABORA UTOPIAN GPO V&P LABORATORIES BANGKOK DRUG NEW LIFE PHARMA PROGRESS MED. SEA PHARM CO T.MAN PHARMA THE MEDIC PHARM BAYER BANGKOK DRUG GREATER PHARM SEA PHARM CO NIDA PHARMA A N B LAB GENERAL HOSPITAL OTSUKA THAI NAKORN PATANA GENERAL HOSPITAL A N B LAB EUROMED GENERAL HOSPITAL OTSUKA THAI NAKORN PATANA A N B LAB GENERAL HOSPITAL 50. A Nursing facility placement appropriate, does not meet target population for mental illness MI ; , mental retardation MR ; , or related condition RC ; . B Nursing facility placement appropriate, no specialized services required. An annual resident review is required. C Nursing facility placement appropriate, specialized services required. An annual resident review is required. D Represents 7-day time-limited approvals. E Represents 30-day time-limited approvals. F Represents 60-day time-limited approvals. J Residents approved for admission only to state psychiatric hospitals. Z Denial for placement in a nursing facility. NOTE: The D, E, and F alphas indicate time-limited stays and the EDS prior approval number PA ; for level of care is also time-limited. Payment will be denied when the PA number is end-dated. Residents who have PASARR numbers with these alpha characters must be closely monitored. If a resident needs to remain in the facility beyond the specified time limit, a Level II screening must be initiated through FHS. Payment will be denied for each day past the time-limited stay. For time-limited stays E and F, a new FL2 must be submitted to EDS as soon as the facility receives the new PASARR number. Margaret O. Langston, RN, Institutional Services, Medical Policy Section DMA, 919-857-4020. Benefit risk profile of comtess remains favourable in the indication as an adjunct to standard preparations of levodopa benserazide or levodopa caridopa for use in patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
|